GB2
Gaetano Burriesci, PhD
Group Leader in Bioengineering
gburriesci@fondazionerimed.com
Go to the Group Page (BE&MD)

Biosketch

Gaetano studied Mechanical Engineering at the University of Palermo, Italy, where he was awarded his MEng degree with first class honours in 1996.  His research activity in biomedical engineering started with his PhD studentship, completed from 1997 to 2000 between the University of Palermo, Italy, and the University of Sheffield, UK, with a thesis that pioneered the application of computer simulations to the design of heart valve systems.  From 2000 to 2002 he worked as a Research Associate at the University of Sheffield, UK, where he contributed to implement fluid-structure interaction models for the physiological simulation of the cardiovascular system, and collaborated with biomedical companies in the development of an innovative synthetic leaflets heart valve.  From 2002 to 2005 Gaetano worked as a Research Manager in the R&D Heart Valve Unit in Sorin Group, Italy (now Corcym, UK), where he oversaw the design, development and assessment of cardiovascular devices and coordinated preclinical tests for the in vitro evaluation of cardiovascular implants.  In 2006 Gaetano took an academic position at University College London (UCL), UK, where he is Professor of Bioengineering.  Since 2017, Gaetano also joined Fondazione Ri.MED, where he has set and directed the Group of Bioengineering & Medical Devices and the Bioengineering Technology Platform.

Scientific Activity

Gaetano’s research activity of covers many disciplines, often combined, which include experimental and numerical stress analysis, non conventional materials and bioengineering.  In recent years, driven by the escalating need for a more sustainable new generation healthcare, Gaetano has focused his activity in the definition of transformative healthcare treatments, by applying his research on novel material technologies, smart structures and advanced engineering approaches to the medical device area.  In collaboration with major biomedical industries, he has led the development of novel therapeutic technologies (over 50 patents) that are now widely adopted and are making a positive impact on the health and quality of life of the patients.

The Group of Bioengineering & Medical Devices
Bioengineering Platform
Back To Top